Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
about
The changing landscape of biosimilars in rheumatologyThe Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesPharmacoeconomics of Biosimilars: What Is There to Gain from Them?Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
P2860
Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Brief Report: Utilization of t ...... e Its Approval in South Korea.
@en
type
label
Brief Report: Utilization of t ...... e Its Approval in South Korea.
@en
prefLabel
Brief Report: Utilization of t ...... e Its Approval in South Korea.
@en
P2093
P2860
P356
P1476
Brief Report: Utilization of t ...... e Its Approval in South Korea.
@en
P2093
Daniel H Solomon
Hong Ji Song
Joongyub Lee
Kyoung-Eun Kwon
Nam-Kyong Choi
Wesley Eddings
Yoon-Kyoung Sung
P2860
P304
P356
10.1002/ART.39546
P577
2015-12-14T00:00:00Z